Detection of DNA Methylation Changes in Body Fluids

Advances in Genetics

Volumn 71, Issue C, 2010, Pages 177-207

  Liloglou, Triantafillos ^a   Field, John K ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; BODY FLUID; DNA METHYLATION; GENETIC EPIGENESIS; HUMAN; METABOLISM; NEOPLASM; QUALITY CONTROL;

BIOLOGICAL MARKERS; BODY FLUIDS; DNA METHYLATION; EPIGENESIS, GENETIC; HUMANS; NEOPLASMS; QUALITY CONTROL;

EID: 77957377060     PISSN: 00652660     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-380864-6.00006-7     Document Type: Book

References (160)

1. Abbaszadegan M.R., Moaven O., Sima H.R., Ghafarzadegan K., A'rabi A., Forghani M.N., Raziee H.R., Mashhadinejad A., Jafarzadeh M., Esmaili-Shandiz E., Dadkhah E. p16 promoter hypermethylation: a useful serum marker for early detection of gastric cancer. World J. Gastroenterol. 2008, 14:2055-2060.
2. Ahrendt S.A., Chow J.T., Xu L.H., Yang S.C., Eisenberger C.F., Esteller M., Herman J.G., Wu L., Decker P.A., Jen J., et al. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J. Natl. Cancer Inst. 1999, 91:332-339.
3. Antill Y.C., Mitchell G., Johnson S.A., Devereux L., Milner A., Di Iulio J., Lindeman G.J., Kirk J., Phillips K.A., Campbell I.G. Gene methylation in breast ductal fluid from BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol. Biomarkers Prev. 2010, 19:265-274.
4. Aparicio A., North B., Barske L., Wang X., Bollati V., Weisenberger D., Yoo C., Tannir N., Horne E., Groshen S., et al. LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors. Epigenetics 2009, 4:176-184.
5. Bae Y.K., Shim Y.R., Choi J.H., Kim M.J., Gabrielson E., Lee S.J., Hwang T.Y., Shin S.O. Gene promoter hypermethylation in tumors and plasma of breast cancer patients. Cancer Res. Treat. 2005, 37:233-240.
6. Ballestar E., Paz M.F., Valle L., Wei S., Fraga M.F., Espada J., Cigudosa J.C., Huang T.H., Esteller M. Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J. 2003, 22:6335-6345.
7. Baryshnikova E., Destro A., Infante M.V., Cavuto S., Cariboni U., Alloisio M., Ceresoli G.L., Lutman R., Brambilla G., Chiesa G., et al. Molecular alterations in spontaneous sputum of cancer-free heavy smokers: results from a large screening program. Clin. Cancer Res. 2008, 14:1913-1919.
8. Baylin S.B., Ohm J.E. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?. Nat. Rev. Cancer 2006, 6:107-116.
9. Belinsky S.A., Klinge D.M., Dekker J.D., Smith M.W., Bocklage T.J., Gilliland F.D., Crowell R.E., Karp D.D., Stidley C.A., Picchi M.A. Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin. Cancer Res. 2005, 11:6505-6511.
10. Belinsky S.A., Liechty K.C., Gentry F.D., Wolf H.J., Rogers J., Vu K., Haney J., Kennedy T.C., Hirsch F.R., Miller Y., et al. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res. 2006, 66:3338-3344.
11. Belinsky S.A., Grimes M.J., Casas E., Stidley C.A., Franklin W.A., Bocklage T.J., Johnson D.H., Schiller J.H. Predicting gene promoter methylation in non-small-cell lung cancer by evaluating sputum and serum. Br. J. Cancer 2007, 96:1278-1283.
12. Bellido M.L., Radpour R., Lapaire O., De Bie I., Hosli I., Bitzer J., Hmadcha A., Zhong X.Y., Holzgreve W. MALDI-TOF Mass Array Analysis of RASSF1A and SERPINB5 Methylation Patterns in Human Placenta and Plasma. Biol. Reprod. 2010, 82:745-750.
13. Bernal C., Aguayo F., Villarroel C., Vargas M., Diaz I., Ossandon F.J., Santibanez E., Palma M., Aravena E., Barrientos C., et al. Reprimo as a potential biomarker for early detection in gastric cancer. Clin. Cancer Res. 2008, 14:6264-6269.
14. Brait M., Ford J.G., Papaiahgari S., Garza M.A., Lee J.I., Loyo M., Maldonado L., Begum S., McCaffrey L., Howerton M., et al. Association between lifestyle factors and CpG island methylation in a cancer-free population. Cancer Epidemiol. Biomarkers Prev. 2009, 18:2984-2991.
15. Bryzgunova O.E., Morozkin E.S., Yarmoschuk S.V., Vlassov V.V., Laktionov P.P. Methylation-specific sequencing of GSTP1 gene promoter in circulating/extracellular DNA from blood and urine of healthy donors and prostate cancer patients. Ann. NY Acad. Sci. 2008, 1137:222-225.
16. Bullinger L., Ehrich M., Dohner K., Schlenk R.F., Dohner H., Nelson M.R., van den Boom D. Quantitative DNA methylation predicts survival in adult acute myeloid leukemia. Blood 2010, 115:636-642.
17. Screening of hereditary pancreatic cancer families 2008, Blackwell, Oxford. C. Carlson, W. Greenhalf, T.A. Brentall (Eds.).
18. Carvalho A.L., Jeronimo C., Kim M.M., Henrique R., Zhang Z., Hoque M.O., Chang S., Brait M., Nayak C.S., Jiang W.W., et al. Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma. Clin. Cancer Res. 2008, 14:97-107.
19. Chan K.C., Ding C., Gerovassili A., Yeung S.W., Chiu R.W., Leung T.N., Lau T.K., Chim S.S., Chung G.T., Nicolaides K.H., et al. Hypermethylated RASSF1A in maternal plasma: A universal fetal DNA marker that improves the reliability of noninvasive prenatal diagnosis. Clin. Chem. 2006, 52:2211-2218.
20. Chang H., Yi B., Li L., Zhang H.Y., Sun F., Dong S.Q., Cao Y. Methylation of tumor associated genes in tissue and plasma samples from liver disease patients. Exp. Mol. Pathol. 2008, 85:96-100.
21. Chim S.S., Tong Y.K., Chiu R.W., Lau T.K., Leung T.N., Chan L.Y., Oudejans C.B., Ding C., Lo Y.M. Detection of the placental epigenetic signature of the maspin gene in maternal plasma. Proc. Natl. Acad. Sci. USA 2005, 102:14753-14758.
22. Chim S.S., Jin S., Lee T.Y., Lun F.M., Lee W.S., Chan L.Y., Jin Y., Yang N., Tong Y.K., Leung T.Y., et al. Systematic search for placental DNA-methylation markers on chromosome 21: toward a maternal plasma-based epigenetic test for fetal trisomy 21. Clin. Chem. 2008, 54:500-511.
23. Chuang C.K., Chu D.C., Tzou R.D., Liou S.I., Chia J.H., Sun C.F. Hypermethylation of the CpG islands in the promoter region flanking GSTP1 gene is a potential plasma DNA biomarker for detecting prostate carcinoma. Cancer Detect. Prev. 2007, 31:59-63.
24. Cirincione R., Lintas C., Conte D., Mariani L., Roz L., Vignola A.M., Pastorino U., Sozzi G. Methylation profile in tumor and sputum samples of lung cancer patients detected by spiral computed tomography: a nested case-control study. Int. J. Cancer 2006, 118:1248-1253.
25. Clayton S.J., Scott F.M., Walker J., Callaghan K., Haque K., Liloglou T., Xinarianos G., Shawcross S., Ceuppens P., Field J.K., et al. K-ras point mutation detection in lung cancer: comparison of two approaches to somatic mutation detection using ARMS allele-specific amplification. Clin. Chem. 2000, 46:1929-1938.
26. de Fraipont F., Moro-Sibilot D., Michelland S., Brambilla E., Brambilla C., Favrot M.C. Promoter methylation of genes in bronchial lavages: a marker for early diagnosis of primary and relapsing non-small cell lung cancer?. Lung Cancer 2005, 50:199-209.
27. Deligezer U., Akisik E.E., Erten N., Dalay N. Sequence-specific histone methylation is detectable on circulating nucleosomes in plasma. Clin. Chem. 2008, 54:1125-1131.
28. Divine K.K., Pulling L.C., Marron-Terada P.G., Liechty K.C., Kang T., Schwartz A.G., Bocklage T.J., Coons T.A., Gilliland F.D., Belinsky S.A. Multiplicity of abnormal promoter methylation in lung adenocarcinomas from smokers and never smokers. Int. J. Cancer 2005, 114:400-405.
29. Dobler C.C., Crawford A.B. Bronchoscopic diagnosis of endoscopically visible lung malignancies: should cytological examinations be carried out routinely?. Intern. Med. J. 2009, 39:806-811.
30. Dulaimi E., Hillinck J., Ibanez de Caceres I., Al-Saleem T., Cairns P. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Clin. Cancer Res. 2004, 10:6189-6193.
31. Dunwell T., Hesson L., Rauch T.A., Wang L., Clark R.E., Dallol A., Gentle D., Catchpoole D., Maher E.R., Pfeifer G.P., et al. A genome-wide screen identifies frequently methylated genes in haematological and epithelial cancers. Mol. Cancer 2010, 9:44.
32. Ehrich M., Field J.K., Liloglou T., Xinarianos G., Oeth P., Nelson M.R., Cantor C.R., van den Boom D. Cytosine methylation profiles as a molecular marker in non-small cell lung cancer. Cancer Res. 2006, 66:10911-10918.
33. Ehrlich S., Weiss D., Burghardt R., Infante-Duarte C., Brockhaus S., Muschler M.A., Bleich S., Lehmkuhl U., Frieling H. Promoter specific DNA methylation and gene expression of POMC in acutely underweight and recovered patients with anorexia nervosa. J. Psychiatr. Res. 2010, Epub ahead of print.
34. Ellinger J., El Kassem N., Heukamp L.C., Matthews S., Cubukluoz F., Kahl P., Perabo F.G., Muller S.C., von Ruecker A., Bastian P.J. Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer. J. Urol. 2008, 179:346-352.
35. Ellinger J., Albers P., Perabo F.G., Muller S.C., von Ruecker A., Bastian P.J. CpG island hypermethylation of cell-free circulating serum DNA in patients with testicular cancer. J. Urol. 2009, 182:324-329.
36. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 2007, 8:286-298.
37. Euhus D.M., Bu D., Ashfaq R., Xie X.J., Bian A., Leitch A.M., Lewis C.M. Atypia and DNA methylation in nipple duct lavage in relation to predicted breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 2007, 16:1812-1821.
38. Fackler M.J., Malone K., Zhang Z., Schilling E., Garrett-Mayer E., Swift-Scanlan T., Lange J., Nayar R., Davidson N.E., Khan S.A., et al. Quantitative multiplex methylation-specific PCR analysis doubles detection of tumor cells in breast ductal fluid. Clin. Cancer Res. 2006, 12:3306-3310.
39. Fackler M.J., Rivers A., Teo W.W., Mangat A., Taylor E., Zhang Z., Goodman S., Argani P., Nayar R., Susnik B., et al. Hypermethylated genes as biomarkers of cancer in women with pathologic nipple discharge. Clin. Cancer Res. 2009, 15:3802-3811.
40. Feng Q., Hawes S.E., Stern J.E., Dem A., Sow P.S., Dembele B., Toure P., Sova P., Laird P.W., Kiviat N.B. Promoter hypermethylation of tumor suppressor genes in urine from patients with cervical neoplasia. Cancer Epidemiol. Biomarkers Prev. 2007, 16:1178-1184.
41. Field J.K., Duffy S.W. Lung cancer screening: the way forward. Br. J. Cancer 2008, 99:557-562.
42. Field J.K., Liloglou T., Xinarianos G., Prime W., Fielding P., Walshaw M.J., Turnbull L. Genetic alterations in bronchial lavage as a potential marker for individuals with a high risk of developing lung cancer. Cancer Res. 1999, 59:2690-2695.
43. Field J.K., Liloglou T., Warrak S., Burger M., Becker E., Berlin K., Nimmrich I., Maier S. Methylation discriminators in NSCLC identified by a microarray based approach. Int. J. Oncol. 2005, 27:105-111.
44. Figueroa M.E., Lugthart S., Li Y., Erpelinck-Verschueren C., Deng X., Christos P.J., Schifano E., Booth J., van Putten W., Skrabanek L., et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 2010, 17:13-27.
45. Fitzgerald J.M., Ramchurren N., Rieger K., Levesque P., Silverman M., Libertino J.A., Summerhayes I.C. Identification of H-ras mutations in urine sediments complements cytology in the detection of bladder tumors. J. Natl. Cancer Inst. 1995, 87:129-133.
46. Friso S., Lamon-Fava S., Jang H., Schaefer E.J., Corrocher R., Choi S.W. Oestrogen replacement therapy reduces total plasma homocysteine and enhances genomic DNA methylation in postmenopausal women. Br. J. Nutr. 2007, 97:617-621.
47. Fryer A.A., Nafee T.M., Ismail K.M., Carroll W.D., Emes R.D., Farrell W.E. LINE-1 DNA methylation is inversely correlated with cord plasma homocysteine in man: a preliminary study. Epigenetics 2009, 4:394-398.
48. Fukushima N., Walter K.M., Uek T., Sato N., Matsubayashi H., Cameron J.L., Hruban R.H., Canto M., Yeo C.J., Goggins M. Diagnosing pancreatic cancer using methylation specific PCR analysis of pancreatic juice. Cancer Biol. Ther. 2003, 2:78-83.
49. Geiman T.M., Muegge K. DNA methylation in early development. Mol. Reprod. Dev. 2010, 77:105-113.
50. Gemma C., Sookoian S., Dieuzeide G., Garcia S.I., Gianotti T.F., Gonzalez C.D., Pirola C.J. Methylation of TFAM gene promoter in peripheral white blood cells is associated with insulin resistance in adolescents. Mol. Genet. Metab. 2010, 100:83-87.
51. Georgiou E., Valeri R., Tzimagiorgis G., Anzel J., Krikelis D., Tsilikas C., Sarikos G., Destouni C., Dimitriadou A., Kouidou S. Aberrant p16 promoter methylation among Greek lung cancer patients and smokers: correlation with smoking. Eur. J. Cancer Prev. 2007, 16:396-402.
52. Gilad S., Meiri E., Yogev Y., Benjamin S., Lebanony D., Yerushalmi N., Benjamin H., Kushnir M., Cholakh H., Melamed N., Bentwich Z., Hod M., et al. Serum microRNAs are promising novel biomarkers. PLoS ONE 2008, 3(9):e3148.
53. Gluckman P.D., Hanson M.A., Buklijas T., Low F.M., Beedle A.S. Epigenetic mechanisms that underpin metabolic and cardiovascular diseases. Nat. Rev. Endocrinol. 2009, 5:401-408.
54. Godler D.E., Tassone F., Loesch D.Z., Taylor A.K., Gehling F., Hagerman R.J., Burgess T., Ganesamoorthy D., Hennerich D., Gordon L., et al. Methylation of novel markers of fragile X alleles is inversely correlated with FMRP expression and FMR1 activation ratio. Hum. Mol. Genet. 2010, 19:1618-1632.
55. Greenhalf W., Grocock C., Harcus M., Neoptolemos J. Screening of high-risk families for pancreatic cancer. Pancreatology 2009, 9:215-222.
56. Grote H.J., Schmiemann V., Geddert H., Rohr U.P., Kappes R., Gabbert H.E., Bocking A. Aberrant promoter methylation of p16(INK4a), RARB2 and SEMA3B in bronchial aspirates from patients with suspected lung cancer. Int. J. Cancer 2005, 116:720-725.
57. Grote H.J., Schmiemann V., Geddert H., Bocking A., Kappes R., Gabbert H.E., Sarbia M. Methylation of RAS association domain family protein 1A as a biomarker of lung cancer. Cancer 2006, 108:129-134.
58. Grutzmann R., Molnar B., Pilarsky C., Habermann J.K., Schlag P.M., Saeger H.D., Miehlke S., Stolz T., Model F., Roblick U.J., et al. Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS ONE 2008, 3:e3759.
59. Haliassos A., Liloglou T., Licourinas M., Doumas C., Ricci N., Spandidos D.A. H ras oncogene mutations in the urine of patients with bladder tumors: description of a non invasive method for the detection of neoplasia. Int. J. Oncol. 1992, 1:4.
60. Hall G.L., Shaw R.J., Field E.A., Rogers S.N., Sutton D.N., Woolgar J.A., Lowe D., Liloglou T., Field J.K., Risk J.M. p16 Promoter methylation is a potential predictor of malignant transformation in oral epithelial dysplasia. Cancer Epidemiol. Biomarkers Prev. 2008, 17:2174-2179.
61. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA 1996, 93:9821-9826.
62. Hoffmann A.C., Kaifi J.T., Vallbohmer D., Yekebas E., Grimminger P., Leers J.M., Izbicki J.R., Holscher A.H., Schneider P.M., Metzger R., et al. Lack of prognostic significance of serum DNA methylation of DAPK, MGMT, and GSTPI in patients with non-small cell lung cancer. J. Surg. Oncol. 2009, 100:414-417.
63. Hoffmann A.C., Vallbohmer D., Prenzel K., Metzger R., Heitmann M., Neiss S., Ling F., Holscher A.H., Schneider P.M., Brabender J. Methylated DAPK and APC promoter DNA detection in peripheral blood is significantly associated with apparent residual tumor and outcome. J. Cancer Res. Clin. Oncol. 2009, 135:1231-1237.
64. Hoque M.O., Begum S., Topaloglu O., Chatterjee A., Rosenbaum E., Van Criekinge W., Westra W.H., Schoenberg M., Zahurak M., Goodman S.N., et al. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J. Natl. Cancer Inst. 2006, 98:996-1004.
65. Hoque M.O., Feng Q., Toure P., Dem A., Critchlow C.W., Hawes S.E., Wood T., Jeronimo C., Rosenbaum E., Stern J., et al. Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J. Clin. Oncol. 2006, 24:4262-4269.
66. Hou L., Wang H., Sartori S., Gawron A., Lissowska J., Bollati V., Tarantini L., Zhang F.F., Zatonski W., Chow W.H., et al. Blood leukocyte DNA hypomethylation and gastric cancer risk in a high-risk Polish population. Int. J. Cancer. 2010, Epub ahead of print.
67. Hsu H.S., Chen T.P., Wen C.K., Hung C.H., Chen C.Y., Chen J.T., Wang Y.C. Multiple genetic and epigenetic biomarkers for lung cancer detection in cytologically negative sputum and a nested case-control study for risk assessment. J. Pathol. 2007, 213:412-419.
68. Iyer P., Zekri A.R., Hung C.W., Schiefelbein E., Ismail K., Hablas A., Seifeldin I.A., Soliman A.S. Concordance of DNA methylation pattern in plasma and tumor DNA of Egyptian hepatocellular carcinoma patients. Exp. Mol. Pathol. 2010, 88:107-111.
69. Jemal A., Center M.M., Ward E., Thun M.J. Cancer occurrence. Methods Mol. Biol. 2009, 471:3-29.
70. Jiang P., Watanabe H., Okada G., Ohtsubo K., Mouri H., Tsuchiyama T., Yao F., Sawabu N. Diagnostic utility of aberrant methylation of tissue factor pathway inhibitor 2 in pure pancreatic juice for pancreatic carcinoma. Cancer Sci. 2006, 97:1267-1273.
71. Jiao L., Zhu J., Hassan M.M., Evans D.B., Abbruzzese J.L., Li D. K-ras mutation and p16 and preproenkephalin promoter hypermethylation in plasma DNA of pancreatic cancer patients: in relation to cigarette smoking. Pancreas 2007, 34:55-62.
72. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128:683-692.
73. Keller A., Leidinger P., Borries A., Wendschlag A., Wucherpfennig F., Scheffler M., Huwer H., Lenhof H.P., Meese E. miRNAs in lung cancer - studying complex fingerprints in patient's blood cells by microarray experiments. BMC Cancer 2009, 9:353.
74. Kim H., Kwon Y.M., Kim J.S., Lee H., Park J.H., Shim Y.M., Han J., Park J., Kim D.H. Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer. J. Clin. Oncol. 2004, 22:2363-2370.
75. King B.L., Tsai S.C., Gryga M.E., D'Aquila T.G., Seelig S.A., Morrison L.E., Jacobson K.K., Legator M.S., Ward D.C., Rimm D.L., et al. Detection of chromosomal instability in paired breast surgery and ductal lavage specimens by interphase fluorescence in situ hybridization. Clin. Cancer Res. 2003, 9:1509-1516.
76. King J.L., Yang B., Sparks A.E., Mains L.M., Murray J.C., Van Voorhis B.J. Skewed X inactivation and IVF-conceived infants. Reprod. Biomed. Online 2010, 20:660-663.
77. Kolesnikova E.V., Tamkovich S.N., Bryzgunova O.E., Shelestyuk P.I., Permyakova V.I., Vlassov V.V., Tuzikov A.S., Laktionov P.P., Rykova E.Y. Circulating DNA in the blood of gastric cancer patients. Ann. NY Acad. Sci. 2008, 1137:226-231.
78. Kronenberg G., Colla M., Endres M. Folic acid, neurodegenerative and neuropsychiatric disease. Curr. Mol. Med. 2009, 9:315-323.
79. Langer P., Kann P.H., Fendrich V., Habbe N., Schneider M., Sina M., Slater E.P., Heverhagen J.T., Gress T.M., Rothmund M., et al. Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut 2009, 58:1410-1418.
80. Lavon I., Refael M., Zelikovitch B., Shalom E., Siegal T. Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades. Neuro. Oncol. 2010, 12:173-180.
81. Lee J.W., Devanarayan V., Barrett Y.C., Weiner R., Allinson J., Fountain S., Keller S., Weinryb I., Green M., Duan L., et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res. 2006, 23:312-328.
82. Lee B.B., Lee E.J., Jung E.H., Chun H.K., Chang D.K., Song S.Y., Park J., Kim D.H. Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer. Clin. Cancer Res. 2009, 15:6185-6191.
83. Liggett T., Melnikov A., Tilwalli S., Yi Q., Chen H., Replogle C., Feng X., Reder A., Stefoski D., Balabanov R., et al. Methylation patterns of cell-free plasma DNA in relapsing-remitting multiple sclerosis. J. Neurol. Sci. 2010, 290:16-21.
84. Liggett T., Melnikov A., Yi Q.L., Replogle C., Brand R., Kaul K., Talamonti M., Abrams R.A., Levenson V. Differential methylation of cell-free circulating DNA among patients with pancreatic cancer versus chronic pancreatitis. Cancer 2010, 116:1674-1680.
85. Ling C., Groop L. Epigenetics: a molecular link between environmental factors and type 2 diabetes. Diabetes 2009, 58:2718-2725.
86. Ling Y., Xu X., Hao J., Ling X., Du X., Liu X., Zhao X. Aberrant methylation of the THRB gene in tissue and plasma of breast cancer patients. Cancer Genet. Cytogenet. 2010, 196:140-145.
87. Liu B.L., Cheng J.X., Zhang W., Zhang X., Wang R., Lin H., Huo J.L., Cheng H. Quantitative detection of multiple gene promoter hypermethylation in tumor tissue, serum, and cerebrospinal fluid predicts prognosis of malignant gliomas. Neuro. Oncol. 2010, 12:540-548.
88. Locke I., Kote-Jarai Z., Fackler M.J., Bancroft E., Osin P., Nerurkar A., Izatt L., Pichert G., Gui G.P., Eeles R.A. Gene promoter hypermethylation in ductal lavage fluid from healthy BRCA gene mutation carriers and mutation-negative controls. Breast Cancer Res. 2007, 9:R20.
89. Lofton-Day C., Model F., Devos T., Tetzner R., Distler J., Schuster M., Song X., Lesche R., Liebenberg V., Ebert M., et al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin. Chem. 2008, 54:414-423.
90. Machida E.O., Brock M.V., Hooker C.M., Nakayama J., Ishida A., Amano J., Picchi M.A., Belinsky S.A., Herman J.G., Taniguchi S., et al. Hypermethylation of ASC/TMS1 is a sputum marker for late-stage lung cancer. Cancer Res. 2006, 66:6210-6218.
91. Matsubayashi H., Sato N., Brune K., Blackford A.L., Hruban R.H., Canto M., Yeo C.J., Goggins M. Age- and disease-related methylation of multiple genes in nonneoplastic duodenum and in duodenal juice. Clin. Cancer Res. 2005, 11:573-583.
92. Matsubayashi H., Canto M., Sato N., Klein A., Abe T., Yamashita K., Yeo C.J., Kalloo A., Hruban R., Goggins M. DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease. Cancer Res. 2006, 66:1208-1217.
93. Melnikov A., Scholtens D., Godwin A., Levenson V. Differential methylation profile of ovarian cancer in tissues and plasma. J. Mol. Diagn. 2009, 11:60-65.
94. Melnikov A.A., Scholtens D., Talamonti M.S., Bentrem D.J., Levenson V.V. Methylation profile of circulating plasma DNA in patients with pancreatic cancer. J. Surg. Oncol. 2009, 99:119-122.
95. Milani L., Lundmark A., Kiialainen A., Nordlund J., Flaegstad T., Forestier E., Heyman M., Jonmundsson G., Kanerva J., Schmiegelow K., et al. DNA methylation for subtype classification and prediction of treatment outcome in patients with childhood acute lymphoblastic leukemia. Blood 2010, 115:1214-1225.
96. Misawa A., Tanaka S., Yagyu S., Tsuchiya K., Iehara T., Sugimoto T., Hosoi H. RASSF1A hypermethylation in pretreatment serum DNA of neuroblastoma patients: a prognostic marker. Br. J. Cancer 2009, 100:399-404.
97. Muretto P., Ruzzo A., Pizzagalli F., Graziano F., Maltese P., Zingaretti C., Berselli E., Donnarumma N., Magnani M. Endogastric capsule for E-cadherin gene (CDH1) promoter hypermethylation assessment in DNA from gastric juice of diffuse gastric cancer patients. Ann. Oncol. 2008, 19:516-519.
98. Ohtsubo K., Watanabe H., Okada G., Tsuchiyama T., Mouri H., Yamaguchi Y., Motoo Y., Okai T., Amaya K., Kitagawa H., et al. A case of pancreatic cancer with formation of a mass mimicking alcoholic or autoimmune pancreatitis in a young man. Possibility of diagnosis by hypermethylation of pure pancreatic juice. JOP 2008, 9:37-45.
99. Palmisano W.A., Divine K.K., Saccomanno G., Gilliland F.D., Baylin S.B., Herman J.G., Belinsky S.A. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 2000, 60:5954-5958.
100. Papadopoulou E., Davilas E., Sotiriou V., Georgakopoulos E., Georgakopoulou S., Koliopanos A., Aggelakis F., Dardoufas K., Agnanti N.J., Karydas I., et al. Cell-free DNA and RNA in plasma as a new molecular marker for prostate and breast cancer. Ann. NY Acad. Sci. 2006, 1075:235-243.
101. Paul T.A., Bies J., Small D., Wolff L. Signatures of polycomb repression and reduced H3K4 trimethylation are associated with p15INK4b DNA methylation in AML. Blood 2010, 115:3098-3108.
102. Payne S.R., Serth J., Schostak M., Kamradt J., Strauss A., Thelen P., Model F., Day J.K., Liebenberg V., Morotti A., et al. DNA methylation biomarkers of prostate cancer: confirmation of candidates and evidence urine is the most sensitive body fluid for non-invasive detection. Prostate 2009, 69:1257-1269.
103. Poley J.W., Kluijt I., Gouma D.J., Harinck F., Wagner A., Aalfs C., van Eijck C.H., Cats A., Kuipers E.J., Nio Y., et al. The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am. J. Gastroenterol. 2009, 104:2175-2181.
104. Pu R.T., Laitala L.E., Clark D.P. Methylation profiling of urothelial carcinoma in bladder biopsy and urine. Acta Cytol. 2006, 50:499-506.
105. Renard I., Joniau S., van Cleynenbreugel B., Collette C., Naome C., Vlassenbroeck I., Nicolas H., de Leval J., Straub J., Van Criekinge W., et al. Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples. Eur. Urol. 2009, 58:96-104.
106. Righini C.A., de Fraipont F., Timsit J.F., Faure C., Brambilla E., Reyt E., Favrot M.C. Tumor-specific methylation in saliva: a promising biomarker for early detection of head and neck cancer recurrence. Clin. Cancer Res. 2007, 13:1179-1185.
107. Rogers C.G., Gonzalgo M.L., Yan G., Bastian P.J., Chan D.Y., Nelson W.G., Pavlovich C.P. High concordance of gene methylation in post-digital rectal examination and post-biopsy urine samples for prostate cancer detection. J. Urol. 2006, 176:2280-2284.
108. Rosas S.L., Koch W., da Costa Carvalho M.G., Wu L., Califano J., Westra W., Jen J., Sidransky D. Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res. 2001, 61:939-942.
109. Roupret M., Hupertan V., Yates D.R., Catto J.W., Rehman I., Meuth M., Ricci S., Lacave R., Cancel-Tassin G., de la Taille A., et al. Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. Clin. Cancer Res. 2007, 13:1720-1725.
110. Russo A.L., Thiagalingam A., Pan H., Califano J., Cheng K.H., Ponte J.F., Chinnappan D., Nemani P., Sidransky D., Thiagalingam S. Differential DNA hypermethylation of critical genes mediates the stage-specific tobacco smoke-induced neoplastic progression of lung cancer. Clin. Cancer Res. 2005, 11:2466-2470.
111. Sakakura C., Hamada T., Miyagawa K., Nishio M., Miyashita A., Nagata H., Ida H., Yazumi S., Otsuji E., Chiba T., et al. Quantitative analysis of tumor-derived methylated RUNX3 sequences in the serum of gastric cancer patients. Anticancer Res. 2009, 29:2619-2625.
112. Sato N., Fukushima N., Maitra A., Matsubayashi H., Yeo C.J., Cameron J.L., Hruban R.H., Goggins M. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res. 2003, 63:3735-3742.
113. Schafer E., Irizarry R., Negi S., McIntyre E., Small D., Figueroa M.E., Melnick A., Brown P. Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting. Blood. 2010, 115:4627-4628.
114. Schmiemann V., Bocking A., Kazimirek M., Onofre A.S., Gabbert H.E., Kappes R., Gerharz C.D., Grote H.J. Methylation assay for the diagnosis of lung cancer on bronchial aspirates: a cohort study. Clin. Cancer Res. 2005, 11:7728-7734.
115. Schumacher A., Weinhäusel A., Petronis A. Application of microarrays for DNA methylation profiling. Methods Mol. Biol. 2008, 439:109-129.
116. Sharma G., Mirza S., Prasad C.P., Srivastava A., Gupta S.D., Ralhan R. Promoter hypermethylation of p16INK4A, p14ARF, CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients. Life Sci. 2007, 80:1873-1881.
117. Sharma P., Kumar J., Garg G., Kumar A., Patowary A., Karthikeyan G., Ramakrishnan L., Brahmachari V., Sengupta S. Detection of altered global DNA methylation in coronary artery disease patients. DNA Cell Biol. 2008, 27:357-365.
118. Sharma G., Mirza S., Parshad R., Srivastava A., Datta Gupta S., Pandya P., Ralhan R. CpG hypomethylation of MDR1 gene in tumor and serum of invasive ductal breast carcinoma patients. Clin. Biochem. 2010, 43:373-379.
119. Shaw R.J., Akufo-Tetteh E.K., Risk J.M., Field J.K., Liloglou T. Methylation enrichment pyrosequencing: combining the specificity of MSP with validation by pyrosequencing. Nucleic Acids Res. 2006, 34:e78.
120. Shaw R.J., Liloglou T., Rogers S.N., Brown J.S., Vaughan E.D., Lowe D., Field J.K., Risk J.M. Promoter methylation of P16, RARbeta, E-cadherin, cyclin A1 and cytoglobin in oral cancer: quantitative evaluation using pyrosequencing. Br. J. Cancer 2006, 94:561-568.
121. Shaw R.J., Hall G.L., Lowe D., Bowers N.L., Liloglou T., Field J.K., Woolgar J.A., Risk J.M. CpG island methylation phenotype (CIMP) in oral cancer: associated with a marked inflammatory response and less aggressive tumour biology. Oral Oncol. 2007, 43:878-886.
122. Shaw R.J., Hall G.L., Woolgar J.A., Lowe D., Rogers S.N., Field J.K., Liloglou T., Risk J.M. Quantitative methylation analysis of resection margins and lymph nodes in oral squamous cell carcinoma. Br. J. Oral Maxillofac. Surg. 2007, 45:617-622.
123. Shaw R.J., Hall G.L., Lowe D., Liloglou T., Field J.K., Sloan P., Risk J.M. The role of pyrosequencing in head and neck cancer epigenetics: correlation of quantitative methylation data with gene expression. Arch. Otolaryngol. Head Neck Surg. 2008, 134:251-256.
124. Shivapurkar N., Stastny V., Xie Y., Prinsen C., Frenkel E., Czerniak B., Thunnissen F.B., Minna J.D., Gazdar A.F. Differential methylation of a short CpG-rich sequence within exon 1 of TCF21 gene: a promising cancer biomarker assay. Cancer Epidemiol. Biomarkers Prev. 2008, 17:995-1000.
125. Shukla S., Mirza S., Sharma G., Parshad R., Gupta S.D., Ralhan R. Detection of RASSF1A and RARbeta hypermethylation in serum DNA from breast cancer patients. Epigenetics 2006, 1:88-93.
126. Smith J.J., Berg C.D. Lung cancer screening: promise and pitfalls. Semin. Oncol. Nurs. 2008, 24:9-15.
127. Smith R.A., Field J.K., Duffy S.W. A global approach to cancer-screening trials. Lancet Oncol. 2008, 9:908-909.
128. Smolarek I., Wyszko E., Barciszewska A.M., Nowak S., Gawronska I., Jablecka A., Barciszewska M.Z. Global DNA methylation changes in blood of patients with essential hypertension. Med. Sci. Monit. 2010, 16:CR149-CR155.
129. Sonpavde G., Aparicio A.M., Zhan F., North B., Delaune R., Garbo L.E., Rousey S.R., Weinstein R.E., Xiao L., Boehm K.A., et al. Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaive castration-resistant prostate cancer. Urol. Oncol. 2009, Epub ahead of print.
130. Stewart D.J., Issa J.P., Kurzrock R., Nunez M.I., Jelinek J., Hong D., Oki Y., Guo Z., Gupta S., Wistuba I.I. Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin. Cancer Res. 2009, 15:3881-3888.
131. Suijkerbuijk K.P., van der Wall E., Vooijs M., van Diest P.J. Molecular analysis of nipple fluid for breast cancer screening. Pathobiology 2008, 75:149-152.
132. Taback B., Saha S., Hoon D.S. Comparative analysis of mesenteric and peripheral blood circulating tumor DNA in colorectal cancer patients. Ann. NY Acad. Sci. 2006, 1075:197-203.
133. Tanzer M., Balluff B., Distler J., Hale K., Leodolter A., Rocken C., Molnar B., Schmid R., Lofton-Day C., Schuster T., et al. Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions. PLoS ONE 2010, 5:e9061.
134. Tessema M., Yu Y.Y., Stidley C.A., Machida E.O., Schuebel K.E., Baylin S.B., Belinsky S.A. Concomitant promoter methylation of multiple genes in lung adenocarcinomas from current, former and never smokers. Carcinogenesis 2009, 30:1132-1138.
135. Topaloglu O., Hoque M.O., Tokumaru Y., Lee J., Ratovitski E., Sidransky D., Moon C.S. Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer. Clin. Cancer Res. 2004, 10:2284-2288.
136. Tsui D.W., Chan K.C., Chim S.S., Chan L.W., Leung T.Y., Lau T.K., Lo Y.M., Chiu R.W. Quantitative aberrations of hypermethylated RASSF1A gene sequences in maternal plasma in pre-eclampsia. Prenat. Diagn. 2007, 27:1212-1218.
137. Umemura S., Fujimoto N., Hiraki A., Gemba K., Takigawa N., Fujiwara K., Fujii M., Umemura H., Satoh M., Tabata M., et al. Aberrant promoter hypermethylation in serum DNA from patients with silicosis. Carcinogenesis 2008, 29:1845-1849.
138. Vaissiere T., Cuenin C., Paliwal A., Vineis P., Hoek G., Krzyzanowski M., Airoldi L., Dunning A., Garte S., Hainaut P., et al. Quantitative analysis of DNA methylation after whole bisulfitome amplification of a minute amount of DNA from body fluids. Epigenetics 2009, 4:221-230.
139. Van der Auwera I., Elst H.J., Van Laere S.J., Maes H., Huget P., van Dam P., Van Marck E.A., Vermeulen P.B., Dirix L.Y. The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients. Br. J. Cancer 2009, 100:1277-1286.
140. van der Drift M.A., Prinsen C.F., Hol B.E., Bolijn A.S., Jeunink M.A., Dekhuijzen P.N., Thunnissen F.B. Can free DNA be detected in sputum of lung cancer patients?. Lung Cancer 2008, 61:385-390.
141. Verri C., Roz L., Conte D., Liloglou T., Livio A., Vesin A., Fabbri A., Andriani F., Brambilla C., Tavecchio L., et al. Fragile histidine triad gene inactivation in lung cancer: the European Early Lung Cancer project. Am. J. Respir. Crit. Care Med. 2009, 179:396-401.
142. Viet C.T., Schmidt B.L. Methylation array analysis of preoperative and postoperative saliva DNA in oral cancer patients. Cancer Epidemiol. Biomarkers Prev. 2008, 17:3603-3611.
143. Vitone L.J., Greenhalf W., Howes N.R., Neoptolemos J.P. Hereditary pancreatitis and secondary screening for early pancreatic cancer. Rocz. Akad. Med. Bialymst. 2005, 50:73-84.
144. Wakabayashi T., Natsume A., Hatano H., Fujii M., Shimato S., Ito M., Ohno M., Ito S., Ogura M., Yoshida J. p16 promoter methylation in the serum as a basis for the molecular diagnosis of gliomas. Neurosurgery 2009, 64:455-461. discussion 461-452.
145. Wang Y.C., Yu Z.H., Liu C., Xu L.Z., Yu W., Lu J., Zhu R.M., Li G.L., Xia X.Y., Wei X.W., et al. Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients. World J. Gastroenterol. 2008, 14:3074-3080.
146. Wang L., Wang F., Guan J., Le J., Wu L., Zou J., Zhao H., Pei L., Zheng X., Zhang T. Relation between hypomethylation of long interspersed nucleotide elements and risk of neural tube defects. Am. J. Clin. Nutr. 2010, 91:1359-1367.
147. Watanabe H., Okada G., Ohtsubo K., Yao F., Jiang P.H., Mouri H., Wakabayashi T., Sawabu N. Aberrant methylation of secreted apoptosis-related protein 2 (SARP2) in pure pancreatic juice in diagnosis of pancreatic neoplasms. Pancreas 2006, 32:382-389.
148. Weaver K.D., Grossman S.A., Herman J.G. Methylated tumor-specific DNA as a plasma biomarker in patients with glioma. Cancer Invest. 2006, 24:35-40.
149. Weber M., Davies J.J., Wittig D., Oakeley E.J., Haase M., Lam W.L., Schubeler D. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat. Genet. 2005, 37:853-862.
150. Widschwendter M., Apostolidou S., Raum E., Rothenbacher D., Fiegl H., Menon U., Stegmaier C., Jacobs I.J., Brenner H. Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study. PLoS ONE 2008, 3:e2656.
151. Wilhelm C.S., Kelsey K.T., Butler R., Plaza S., Gagne L., Zens M.S., Andrew A.S., Morris S., Nelson H.H., Schned A.R., et al. Implications of LINE1 Methylation for Bladder Cancer Risk in Women. Clin. Cancer Res. 2010, 16:1682-1689.
152. Wong I.H., Zhang J., Lai P.B., Lau W.Y., Lo Y.M. Quantitative analysis of tumor-derived methylated p16INK4a sequences in plasma, serum, and blood cells of hepatocellular carcinoma patients. Clin. Cancer Res. 2003, 9:1047-1052.
153. Xiong Z., Laird P.W. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res. 1997, 25:2532-2534.
154. Yan L., McFaul C., Howes N., Leslie J., Lancaster G., Wong T., Threadgold J., Evans J., Gilmore I., Smart H., et al. Molecular analysis to detect pancreatic ductal adenocarcinoma in high-risk groups. Gastroenterology 2005, 128:2124-2130.
155. Yates D.R., Rehman I., Meuth M., Cross S.S., Hamdy F.C., Catto J.W. Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls. Oncogene 2006, 25:1984-1988.
156. Yazici H., Terry M.B., Cho Y.H., Senie R.T., Liao Y., Andrulis I., Santella R.M. Aberrant methylation of RASSF1A in plasma DNA before breast cancer diagnosis in the Breast Cancer Family Registry. Cancer Epidemiol. Biomarkers Prev. 2009, 18:2723-2725.
157. Zhang Y.J., Rossner P., Chen Y., Agrawal M., Wang Q., Wang L., Ahsan H., Yu M.W., Lee P.H., Santella R.M. Aflatoxin B1 and polycyclic aromatic hydrocarbon adducts, p53 mutations and p16 methylation in liver tissue and plasma of hepatocellular carcinoma patients. Int. J. Cancer 2006, 119:985-991.
158. Zhang Y.J., Wu H.C., Shen J., Ahsan H., Tsai W.Y., Yang H.I., Wang L.Y., Chen S.Y., Chen C.J., Santella R.M. Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin. Cancer Res. 2007, 13:2378-2384.
159. Zhu W., Qin W., Hewett J.E., Sauter E.R. Quantitative evaluation of DNA hypermethylation in malignant and benign breast tissue and fluids. Int. J. Cancer 2010, 126:474-482.
160. Zochbauer-Muller S., Lam S., Toyooka S., Virmani A.K., Toyooka K.O., Seidl S., Minna J.D., Gazdar A.F. Aberrant methylation of multiple genes in the upper aerodigestive tract epithelium of heavy smokers. Int. J. Cancer 2003, 107:612-616.